Rohtak News Magazine

The Severe Hypertriglyceridemia Market is Expected to Increase with a CAGR of 8.1% During the Study Period (2019-32) | DelveInsight

 Breaking News
  • No posts were found

The Severe Hypertriglyceridemia Market is Expected to Increase with a CAGR of 8.1% During the Study Period (2019-32) | DelveInsight

September 01
02:04 2022
The Severe Hypertriglyceridemia Market is Expected to Increase with a CAGR of 8.1% During the Study Period (2019-32) | DelveInsight

DelveInsight’s Severe Hypertriglyceridemia Market Insights report includes a comprehensive understanding of current treatment practices, Severe Hypertriglyceridemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.

 

The overall Severe Hypertriglyceridemia market is expected to increase due to the rising prevalent cases over the globe and thus the surge in treatment options. In addition, the expected launch of emerging therapies will boost the Severe Hypertriglyceridemia market in the forecasted period (2022–2032).

 

Key Takeaways from the Severe Hypertriglyceridemia Market Report

  • As per DelveInsight analysis, the Severe Hypertriglyceridemia market size in the 7MM was found to be approximately USD 3,060 million in 2021.
  • As per the estimates, the total number of Hypertriglyceridemia prevalent cases associated in 7MM countries was approximately 154 million in 2021, out of which approximately 3 million cases were diagnosed prevalent cases of Severe Hypertriglyceridemia. 
  • Leading Severe Hypertriglyceridemia companies Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., Afimmune Pharmaceutical, NorthSea Therapeutics B.V., Amryt Pharma, and others are working to develop a new medication for Severe Hypertriglyceridemia which can be available in the Severe Hypertriglyceridemia market in the upcoming years.
  • The Severe Hypertriglyceridemia therapies in the pipeline include Olezarsen, Pegozafermin (BIO89-100), ARO-APOC3, Epeleuton (DS102), NST-1024 (SEFA 1024), Lomitapide, and others.
  • The expected launch of therapies and the increasing prevalence will lead to Severe Hypertriglyceridemia market growth during the forecast period. 

 

Download Sample Report- https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-market

 

Severe Hypertriglyceridemia Overview

Triglycerides are fats synthesized by the liver or, in the case of those derived from dietary sources, are ingested by the liver; the triglycerides are subsequently transported throughout the circulation by triglyceride-rich lipoproteins. Most of the elevations of triglycerides are mild to moderate in nature, and the pathophysiology involves hepatic overproduction of very-low-density lipoproteins (VLDLs).

 

Severe Hypertriglyceridemia Epidemiology Segmentation in the 7MM

  • Severe Hypertriglyceridemia Prevalent Cases
  • Severe Hypertriglyceridemia Diagnosed Prevalent Cases
  • Severe Hypertriglyceridemia Severity-specific Diagnosed Prevalent Cases
  • Severe Hypertriglyceridemia Etiology-specific Diagnosed Prevalent Cases

 

Severe Hypertriglyceridemia Treatment Market

Popular Hypertriglyceridemia treatment guidelines, such as the AHA/ACC lipid treatment guidelines, recommend addressing and treating lifestyle factors, secondary variables such as diabetes mellitus, chronic liver or kidney disease, and/or nephrotic syndrome, hypothyroidism, and drugs that elevate triglycerides. If serum triglycerides remain elevated after adjusting these parameters, pharmaceutical therapy should be considered. The goal of pharmacological treatment is to lower triglyceride levels while also lowering the risk of pancreatitis and cardiovascular disease in people with severe hypertriglyceridemia.

 

Severe Hypertriglyceridemia Pipeline Therapies and Key Companies

  • Olezarsen: Ionis Pharmaceuticals
  • Pegozafermin (BIO89-100): 89bio, Inc.
  • ARO-APOC3: Arrowhead Pharmaceuticals, Inc.
  • Epeleuton (DS102): Afimmune Pharmaceutical
  • NST-1024 (SEFA 1024): NorthSea Therapeutics B.V.
  • Lomitapide: Amryt Pharma
  • Others

 

Severe Hypertriglyceridemia Market Dynamics

The present unmet need of the Severe Hypertriglyceridemia market is for medications with improved safety and efficacy that give an optimal cure. The growing prevalence of primary and secondary causes, as well as the increasing number of episodes of primary and secondary causes, are anticipated to result in an increase in Severe Hypertriglyceridemia treatment choices across the globe. As a result, the Severe Hypertriglyceridemia market will experience an increase in the coming year. Furthermore, the increasing awareness and updates in diagnosis and treatment guidelines will boost the Severe Hypertriglyceridemia market. 

 

Scope of the Severe Hypertriglyceridemia Market Report

  • Study Period: 2019-2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Severe Hypertriglyceridemia Companies: Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., Afimmune Pharmaceutical, NorthSea Therapeutics B.V., Amryt Pharma, and others
  • Key Severe Hypertriglyceridemia Therapies: Olezarsen, Pegozafermin (BIO89-100), ARO-APOC3, Epeleuton (DS102), NST-1024 (SEFA 1024), Lomitapide, and others
  • Therapeutic Assessment: Severe Hypertriglyceridemia current marketed and emerging therapies
  • Severe Hypertriglyceridemia Market Dynamics:  Severe Hypertriglyceridemia market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Severe Hypertriglyceridemia Market Access and Reimbursement

 

Request Sample Report- https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-market

 

Table of content

1. Key Insights

2. Report Introduction

3. Severe Hypertriglyceridemia Market Overview at a Glance

4. Executive Summary of Severe Hypertriglyceridemia

5. Key Events

6. Disease Background and Overview

7. Epidemiology and Patient Population

8. Patient Journey

9. Marketed Drugs

10. Emerging Drugs

11. Severe Hypertriglyceridemia: Seven Major Market Analysis

12. KOL Views

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. Unmet Needs

17. Reimbursement and Market Access

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

Do you have any query related to the report? Visit here- https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-market

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles